![Marinus Pharmaceuticals Inc](/common/images/company/N_MRNS.png)
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychi... Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy. Show more
The Gross Law Firm Notifies Marinus Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - MRNS PR Newswire NEW YORK, July 25, 2024 NEW YORK, July 25, 2024 /PRNewswire/...
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the China National...
Marinus Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before August 5, 2024 to Discuss Your Rights - MRNS PR Newswire NEW YORK, July 17...
Shareholders that lost money on Marinus Pharmaceuticals, Inc.(MRNS) should contact The Gross Law Firm about pending Class Action - MRNS PR Newswire NEW YORK, July 12, 2024 NEW YORK, July 12, 2024...
The Gross Law Firm Reminds Marinus Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 5, 2024 - MRNS PR Newswire NEW YORK, July 3, 2024 NEW YORK, July 3, 2024...
Marinus Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before August 5, 2024 to Discuss Your Rights - MRNS PR Newswire NEW YORK, June 28, 2024 NEW YORK...
RAISE trial met its first co-primary endpoint demonstrating rapid cessation of status epilepticus in a highly refractory patient population The trial failed to achieve statistical significance on...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.075 | 5.45454545455 | 1.375 | 1.52 | 1.365 | 378278 | 1.44619281 | CS |
4 | 0.21 | 16.935483871 | 1.24 | 1.54 | 1.1 | 1050980 | 1.27209036 | CS |
12 | -0.05 | -3.33333333333 | 1.5 | 1.77 | 1.1 | 1112356 | 1.36576456 | CS |
26 | -8.7 | -85.7142857143 | 10.15 | 10.5 | 1.1 | 1404025 | 2.43436018 | CS |
52 | -8.15 | -84.8958333333 | 9.6 | 11.26 | 1.1 | 975216 | 3.98751449 | CS |
156 | -14.78 | -91.0659272951 | 16.23 | 16.49 | 1.1 | 591631 | 5.76391873 | CS |
260 | 0.26 | 21.8487394958 | 1.19 | 20.04 | 1 | 1035296 | 4.42527719 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.